Safety evaluation of the preemptive immune-cell therapy against cancer.
- Conditions
- none
- Registration Number
- JPRN-jRCTc030190259
- Lead Sponsor
- Goto Shigenori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 650
(1)Have risk factors for cancer and desire for receiving the preemptive immune-cell therapy.
(2)Be > 18 of age when obtaining the informed consent.
(3)Provide written informed consent.
(4)Be determined to be appropriate by the doctor in charge.
(1)Be diagnosed with cancer.
(2)Desire to receive the immune-cell therapy for the treatment of any allergic disease.
(3)Be HIV or HTLV-1 positive.
(4)Be an allotransplant recipient.
(5)Have a history or sign of interstitial pneumonia.
(6)Have an active autoimmune disease.
(7)Be a female who is pregnant, nursing, or of childbearing potential.
(8)A subject 70 years of age and above must be carefully considered for the risk of an autoimmune disease to enroll in this study.
(9)Be determined to be inappropriate by the doctor in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, Immunological response
- Secondary Outcome Measures
Name Time Method Efficacy